| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 118.18 | 36 |
| Intrinsic value (DCF) | 37.01 | -57 |
| Graham-Dodd Method | 54.43 | -37 |
| Graham Formula | 49.02 | -44 |
Vetoquinol SA is a leading veterinary pharmaceutical company headquartered in Lure, France, specializing in the design, development, and sale of veterinary drugs and non-medicinal products. Founded in 1933, the company operates across Europe, the Americas, and the Asia Pacific region, offering a diverse portfolio targeting mobility, pain, inflammation, dermatology, hygiene, anti-parasite, udder health, infectious diseases, reproduction, behavior management, internal medicine, and cardiology-nephrology for livestock and companion animals. As a subsidiary of Soparfin SCA, Vetoquinol SA is well-positioned in the growing global veterinary healthcare market, benefiting from increasing pet ownership and livestock health awareness. The company’s strong R&D capabilities and strategic geographic presence make it a key player in the specialty veterinary pharmaceuticals sector.
Vetoquinol SA presents a stable investment opportunity with a market capitalization of €856.6 million and a beta of 0.783, indicating lower volatility compared to the broader market. The company reported €539.2 million in revenue and €58.7 million in net income for the latest fiscal year, with a diluted EPS of €4.98. Strong operating cash flow of €85.8 million and a healthy cash position of €206.3 million provide financial flexibility. However, investors should note the modest dividend yield (€0.85 per share) and the competitive pressures in the veterinary pharmaceutical industry. The company’s focus on innovation and geographic diversification could drive long-term growth, but regulatory risks and market competition remain key considerations.
Vetoquinol SA competes in the global veterinary pharmaceutical market, leveraging its strong R&D capabilities and diversified product portfolio. The company’s competitive advantage lies in its specialized focus on both livestock and companion animals, catering to a broad customer base. Its geographic presence across Europe, the Americas, and Asia Pacific provides resilience against regional market fluctuations. However, the industry is highly competitive, with larger players like Zoetis and Elanco dominating market share. Vetoquinol’s smaller scale may limit its ability to compete on pricing and marketing spend, but its niche expertise in certain therapeutic areas (e.g., udder health, anti-parasite) allows for differentiation. The company’s financial stability and low debt (€21.1 million) provide a solid foundation, but it must continue investing in innovation to maintain its competitive edge.